CA-C3.AI
21.12.2021 15:02:07 CET | Business Wire | Press release
The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to advance the science of digital transformation with artificial intelligence (AI) designed to harden information security (Infosec) and secure critical infrastructure.
“Cybersecurity is an existential issue,” said Thomas M. Siebel, Chairman and CEO of C3 AI, a leading enterprise AI software provider. “We are assembling the best minds on the planet to develop innovative AI to attain a step-function improvement in securing IT, OT, and critical infrastructure systems.”
“Advanced AI and machine learning offer the best opportunity to design robust defensive systems,” said C3.ai DTI Co-Director S. Shankar Sastry of UC Berkeley, whose area of research expertise is cybersecurity. “This call for proposals will help design the defenses necessary to securely shield the digital transformation of our economy.”
“We aim to develop AI techniques to identify and neutralize malware, ransomware, phishing attacks, and prevent the weaponization of innocent insiders,” said C3.ai DTI Co-Director R. Srikant of the University of Illinois at Urbana-Champaign, an expert in AI and networks.
Immediate Call for Proposals: AI to Transform Cybersecurity and Secure Critical Infrastructure.
Topics for research awards may include, but are not limited to, the following:
- AI techniques to identify previously unknown malware, ransomware, and zero-day vulnerabilities, enabling isolation and neutralization
- AI-enabled network and system crawlers that can continuously search and identify persistent access mechanisms (backdoors), bots, remote access toolkits (RATS), stagers, and Trojans
- AI forensics and attribution techniques to identify sources of attacks
- AI techniques to automate simulated adversarial attacks to identify system and network vulnerabilities
- AI techniques to accurately identify and enable the neutralization of phishing attacks
- Change management techniques to prevent the weaponization of innocent insiders
- AI techniques to detect the presence of advanced persistent threats and insider threats
- AI-enabled network and/or system crawlers that access and continuously evaluate system security levels
- AI techniques, perhaps in supervised or unsupervised learning, to provide early detection of system and/or network anomalies that might be indicative of unauthorized access, denial of service, or data exfiltration
- Techniques and methods to enable the development of AI algorithms that are resilient to adversarial attacks
- AI techniques to identify concentration risk in the software and computer supply chain
- Change management to transform organizational behavior to manifest best practices in cyber hygiene
- Techniques to respond to attacks at the organizational and societal level
This third call for proposals is open now, with a submission deadline of February 7, 2022 . Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai . Award winners will be announced in March 2022, with a start date around June 1, 2022. Award winners may take part in the annual C3.ai DTI Research Symposium, to be held March 22-24, 2022, in Miami, Florida.
Up to USD $10 million in cash awards will be funded from this third call, ranging from USD $100,000 to $1,000,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite hosted on the Microsoft Azure Cloud, and access to high-performance computing resources at the Lawrence Berkeley National Laboratory and the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign. All science developed from C3.ai DTI funded projects accrues to the public domain.
Establishing the New Science of Digital Transformation
C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.
About C3.ai Digital Transformation Institute
C3.ai Digital Transformation Institute
represents an innovative vision to take AI, ML, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom